This announcement is a separate document:
アステラス製薬：前立腺がん治療剤XTANDI 中国で適応追加に関する承認を取得
Astellas Pharma: XTANDI, a prostate cancer treatment, has obtained approval for additional indications in China.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.